244 related articles for article (PubMed ID: 7689420)
21. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
23. Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Moriyama K; Kouchi Y; Morinaga H; Irimura K; Hayashi T; Ohuchida A; Goto T; Yoshizawa Y
Toxicology; 2006 Jan; 217(2-3):233-9. PubMed ID: 16278042
[TBL] [Abstract][Full Text] [Related]
24. Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.
Fujii S; Kitano S; Ikenaka K; Fukushima M; Nakamura H; Maehara Y; Shirasaka T
Gan; 1980 Feb; 71(1):100-6. PubMed ID: 6769735
[TBL] [Abstract][Full Text] [Related]
25. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
[TBL] [Abstract][Full Text] [Related]
26. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
27. [The mechanism of potentiation of the antitumor effect of 5-fluorouracil by methionine-free intravenous amino acid solution (AO-90) in rats].
Hibino Y; Kawarabayashi Y; Kohri H; Ueda N; Tsukagoshi S
Gan To Kagaku Ryoho; 1994 Sep; 21(12):2021-8. PubMed ID: 8085853
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
29. [Experimental studies on the optimal therapeutic mode of intra-arterial infusion of 5-fluorouracil. (2) Concentrations within the tumors and normal tissues and therapeutic and adverse effects of 5-fluorouracil delivered by various routes].
Ota J
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2362-9. PubMed ID: 6639098
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii S; Fukushima M; Shimamoto Y; Shirasaka T
Jpn J Cancer Res; 1989 Jun; 80(6):509-12. PubMed ID: 2503471
[TBL] [Abstract][Full Text] [Related]
31. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
32. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
34. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
36. [Experimental studies on the optimal therapeutic mode of intra-arterial infusion of 5-fluorouracil. (1) Preparation of an animal model for continuous intra-arterial infusion and comparison of the therapeutic and adverse effects of 5-fluorouracil delivered by various modes].
Ota J
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2353-61. PubMed ID: 6639097
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of continuous venous infusion of 5-FU and FT-207 under total parenteral nutrition].
Tane S; Ogawa Y; Kido Y; Naruko M; Niwa H; Abe Y; Kobayashi M; Mori T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2947-53. PubMed ID: 3094454
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacodynamic study on the effectiveness of UFT against cancer of gastro-intestinal (GI) tract].
Seo Y; Matsuoka H; Kakeji Y; Morita M; Ohno S; Matsukuma A; Tomoda H; Furusawa M
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1775-80. PubMed ID: 8379669
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
